Mark Zafereo
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark Zafereo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06959511 · Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryM.D. Anderson Cancer Center · recruiting · Neoadjuvant Treatment, Thyroid Cancer · principal investigator
- Ph2NCT04759911 · Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerM.D. Anderson Cancer Center · active not recruiting · Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma · principal investigator
- Ph2NCT04675710 · Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerM.D. Anderson Cancer Center · active not recruiting · Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:36 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed